CR20170456A - Composiciones farmacéuticas para terapias combinadas - Google Patents
Composiciones farmacéuticas para terapias combinadasInfo
- Publication number
- CR20170456A CR20170456A CR20170456A CR20170456A CR20170456A CR 20170456 A CR20170456 A CR 20170456A CR 20170456 A CR20170456 A CR 20170456A CR 20170456 A CR20170456 A CR 20170456A CR 20170456 A CR20170456 A CR 20170456A
- Authority
- CR
- Costa Rica
- Prior art keywords
- insulin
- blood glucose
- sensitivity
- pharmaceutical compositions
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Abstract
Una composición farmacéutica que comprende una combinación de un agonista del FXR y por lo menos un agente terapéutico adicional que reduce el nivel de glucosa en sangre, estimula la secreción de insulina y/o aumenta la sensibilidad a la insulina. También se relaciona con el uso de la composición farmacéutica para el tratamiento o la prevención de una enfermedad o condición mediada por FXR, como por ejemplo NAFLD y NASH, una enfermedad o condición relacionada con un nivel elevado de glucosa en sangre, una la reducción de la secreción de insulina y/o la reducción de la sensibilidad a la insulina, tal como hiperglucemia, diabetes, obesidad y resistencia a la insulina, o para disminuir el nivel de glucosa en sangre, estimular la secreción de insulina y/o aumentar la sensibilidad a la insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562144040P | 2015-04-07 | 2015-04-07 | |
PCT/US2016/026146 WO2016164413A1 (en) | 2015-04-07 | 2016-04-06 | Pharmaceutical compositions for combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20170456A true CR20170456A (es) | 2018-06-13 |
Family
ID=57072872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20170456A CR20170456A (es) | 2015-04-07 | 2016-04-06 | Composiciones farmacéuticas para terapias combinadas |
Country Status (23)
Country | Link |
---|---|
US (1) | US10894054B2 (es) |
EP (1) | EP3280421B1 (es) |
JP (1) | JP6879931B2 (es) |
KR (1) | KR20170132879A (es) |
CN (1) | CN107613986A (es) |
AR (1) | AR104195A1 (es) |
AU (1) | AU2016246524B2 (es) |
BR (1) | BR112017021311A2 (es) |
CA (1) | CA2981507A1 (es) |
CL (2) | CL2017002538A1 (es) |
CO (1) | CO2017010292A2 (es) |
CR (1) | CR20170456A (es) |
EA (1) | EA036757B1 (es) |
EC (1) | ECSP17073004A (es) |
IL (2) | IL254772A0 (es) |
MA (1) | MA41083A1 (es) |
MX (1) | MX2017012893A (es) |
NI (1) | NI201700121A (es) |
PE (1) | PE20180034A1 (es) |
SV (1) | SV2017005539A (es) |
TN (1) | TN2017000426A1 (es) |
TW (1) | TW201642869A (es) |
WO (1) | WO2016164413A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
AU2015267148B2 (en) | 2014-05-28 | 2021-07-29 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
EP3207123A1 (en) | 2014-10-17 | 2017-08-23 | Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
WO2017182873A2 (en) | 2016-04-19 | 2017-10-26 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
WO2017192997A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
CN117229994A (zh) * | 2016-11-04 | 2023-12-15 | 儿童医院医学中心 | 肝类器官疾病模型以及其制备和使用方法 |
NZ753873A (en) | 2016-12-05 | 2023-01-27 | Children’S Hospital Medical Center | Colonic organoids and methods of making and using same |
CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
SG11202010521VA (en) * | 2018-04-24 | 2020-11-27 | Ph Pharma Co Ltd | Use of neutrophil elastase inhibitors in liver disease |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
US20210393662A1 (en) * | 2018-10-18 | 2021-12-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
EP3886892A1 (en) * | 2018-11-30 | 2021-10-06 | UREKA Sarl | Peptide-oligourea foldamer compounds and methods of their use |
JP2022527762A (ja) * | 2019-03-26 | 2022-06-06 | インターセプト ファーマシューティカルズ, インコーポレイテッド | オベチコール酸を用いた肝疾患の診断および処置の方法 |
EP3946333A1 (en) * | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
WO2021029656A1 (ko) * | 2019-08-14 | 2021-02-18 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물 |
WO2023225507A1 (en) * | 2022-05-16 | 2023-11-23 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
WO2023240204A2 (en) * | 2022-06-08 | 2023-12-14 | Kojin Therapeutics, Inc. | Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US20030109467A1 (en) | 2001-11-15 | 2003-06-12 | Isis Pharmaceuticals Inc. | Antisense modulation of human FXR expression |
DE69940958D1 (de) | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
US6465258B1 (en) | 1999-01-07 | 2002-10-15 | Tularik, Inc. | FXR receptor-mediated modulation cholesterol metabolism |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
DK1169312T3 (da) * | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Glucokinaseaktivatorer |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
DK1392714T3 (da) | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
CA2482195A1 (en) * | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
RS20060320A (en) | 2003-08-01 | 2008-08-07 | Janssen Pharmaceutica N.V., | Substituted indazole-o-glucosides |
EA009768B1 (ru) * | 2003-08-01 | 2008-04-28 | Янссен Фармацевтика Нв | Замещенные конденсированные гетероциклические с-гликозиды |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
EP2712617B2 (en) | 2004-03-12 | 2020-11-18 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using Fxr ligands |
US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
US20090239796A1 (en) * | 2005-08-19 | 2009-09-24 | Amylin Pharmaceuticals, Inc. | Methods for treating diabetes and reducing body weight |
US8389472B2 (en) | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
EP1962838B1 (en) * | 2005-12-19 | 2011-09-28 | GlaxoSmithKline LLC | Farnesoid x receptor agonists |
BRPI0707794A2 (pt) | 2006-02-14 | 2011-05-10 | Intercept Pharmaceuticals Inc | compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos |
JP5225984B2 (ja) | 2006-05-24 | 2013-07-03 | イーライ リリー アンド カンパニー | Fxrを調節する化合物及び方法 |
PL2029547T3 (pl) | 2006-05-24 | 2010-09-30 | Lilly Co Eli | Agoniści FXR |
DK2040713T3 (da) | 2006-06-27 | 2014-09-29 | Intercept Pharmaceuticals Inc | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
US20080299118A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
US20080300235A1 (en) | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
US20090215748A1 (en) | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
US20100056546A1 (en) * | 2008-09-04 | 2010-03-04 | Auspex Pharmaceuticals, Inc. | Sulfonylurea inhibitors of atp-sensitive potassium channels |
US8685934B2 (en) | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
KR101822608B1 (ko) | 2010-02-24 | 2018-01-29 | 리립사, 인크. | 담즙산 격리제로서 사용하기 위한 아민 폴리머 |
EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
WO2011150285A1 (en) | 2010-05-26 | 2011-12-01 | Adm Tronics Unlimited Inc. | Apparatus and method for uroflowmetry |
EP2617514A4 (en) | 2010-09-15 | 2018-01-03 | Sumitomo Electric Industries, Ltd. | Laser processing method |
WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
CA3028207A1 (en) | 2012-06-19 | 2013-12-27 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
UA118673C2 (uk) * | 2013-05-14 | 2019-02-25 | Інтерсепт Фармасутікалз, Інк. | Похідні 11-гідроксилу жовчних кислот та їх амінокислотні кон'югати як модулятори фарнезоїдного x-рецептора |
AR103624A1 (es) | 2015-02-06 | 2017-05-24 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia de combinación |
-
2016
- 2016-04-06 KR KR1020177031857A patent/KR20170132879A/ko not_active Application Discontinuation
- 2016-04-06 MX MX2017012893A patent/MX2017012893A/es unknown
- 2016-04-06 CN CN201680029144.7A patent/CN107613986A/zh active Pending
- 2016-04-06 AU AU2016246524A patent/AU2016246524B2/en not_active Ceased
- 2016-04-06 PE PE2017001987A patent/PE20180034A1/es unknown
- 2016-04-06 CR CR20170456A patent/CR20170456A/es unknown
- 2016-04-06 TN TNP/2017/000426A patent/TN2017000426A1/en unknown
- 2016-04-06 EA EA201792203A patent/EA036757B1/ru unknown
- 2016-04-06 CA CA2981507A patent/CA2981507A1/en not_active Abandoned
- 2016-04-06 US US15/564,799 patent/US10894054B2/en active Active
- 2016-04-06 BR BR112017021311A patent/BR112017021311A2/pt not_active IP Right Cessation
- 2016-04-06 EP EP16777168.2A patent/EP3280421B1/en active Active
- 2016-04-06 WO PCT/US2016/026146 patent/WO2016164413A1/en active Application Filing
- 2016-04-06 JP JP2017553131A patent/JP6879931B2/ja active Active
- 2016-04-06 MA MA41083A patent/MA41083A1/fr unknown
- 2016-04-07 AR ARP160100929A patent/AR104195A1/es unknown
- 2016-04-07 TW TW105110879A patent/TW201642869A/zh unknown
-
2017
- 2017-09-28 IL IL254772A patent/IL254772A0/en unknown
- 2017-10-05 SV SV2017005539A patent/SV2017005539A/es unknown
- 2017-10-05 NI NI201700121A patent/NI201700121A/es unknown
- 2017-10-06 CL CL2017002538A patent/CL2017002538A1/es unknown
- 2017-10-10 CO CONC2017/0010292A patent/CO2017010292A2/es unknown
- 2017-11-01 EC ECIEPI201773004A patent/ECSP17073004A/es unknown
-
2018
- 2018-04-19 CL CL2018001007A patent/CL2018001007A1/es unknown
-
2019
- 2019-07-29 IL IL268316A patent/IL268316B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP17073004A (es) | 2018-02-28 |
WO2016164413A1 (en) | 2016-10-13 |
BR112017021311A2 (pt) | 2018-06-26 |
EP3280421A1 (en) | 2018-02-14 |
EP3280421A4 (en) | 2019-08-28 |
CN107613986A (zh) | 2018-01-19 |
IL268316B (en) | 2022-02-01 |
AR104195A1 (es) | 2017-07-05 |
CO2017010292A2 (es) | 2018-01-05 |
IL254772A0 (en) | 2017-12-31 |
KR20170132879A (ko) | 2017-12-04 |
EA201792203A1 (ru) | 2018-02-28 |
NI201700121A (es) | 2018-01-10 |
MX2017012893A (es) | 2018-01-15 |
JP2018510900A (ja) | 2018-04-19 |
CA2981507A1 (en) | 2016-10-13 |
EA036757B1 (ru) | 2020-12-17 |
MA41083A1 (fr) | 2018-05-31 |
JP6879931B2 (ja) | 2021-06-02 |
US20180117065A1 (en) | 2018-05-03 |
SV2017005539A (es) | 2019-01-18 |
US10894054B2 (en) | 2021-01-19 |
IL268316A (en) | 2019-09-26 |
AU2016246524A1 (en) | 2017-10-26 |
CL2018001007A1 (es) | 2018-06-15 |
CL2017002538A1 (es) | 2018-04-20 |
AU2016246524B2 (en) | 2021-04-01 |
PE20180034A1 (es) | 2018-01-09 |
EP3280421B1 (en) | 2023-12-27 |
TN2017000426A1 (en) | 2019-04-12 |
TW201642869A (zh) | 2016-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017010292A2 (es) | Composiciones farmacéuticas para terapias combinadas | |
EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
CL2016003069A1 (es) | Composición para tratar la diabetes mellitus, que comprende conjugados de variantes de insulina humana y una región fc, y además comprende un conjugado compuesto por un agonista doble de glp-/glucagón y una región fc | |
AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
EA201590759A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
PH12019502655A1 (en) | Acylated insulin compound | |
CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
MX366685B (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
CL2015001574A1 (es) | Terapia combinada para el cancer | |
UY37061A (es) | Administracion intradermica de una composicion de inmunoglobulina g | |
PH12019550216A1 (en) | Compositions for treatment of hyperglycemia in diabetes mellitus patients | |
Klossowski | Maculopapular rash: case report | |
Upasi | Homoeopathic remedies: the physics of healing with microdoses | |
EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
CL2009000621A1 (es) | Uso de un agonista selectivo del receptor s1p1 para preparar un medicamento util en el tratamiento de enfermedades o trastornos asociados con un sistema inmune activado. |